Cinctive Capital Management LP Neurocrine Biosciences Inc Transaction History

Cinctive Capital Management LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$130.4 - $143.74 $1.3 Million - $1.43 Million	9,983 New	9,983 $1.38 Million
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $4.91 Million - $6.43 Million	-67,825 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $2.86 Million - $3.82 Million	-35,948 Reduced 34.64%	67,825 $5.78 Million
Q3 2021 Nov 15, 2021	BUY	$86.18 - $99.03 $2.3 Million - $2.65 Million	26,734 Added 34.7%	103,773 $9.95 Million
Q2 2021 Aug 16, 2021	BUY	$89.43 - $102.27 $2.53 Million - $2.89 Million	28,248 Added 57.9%	77,039 $7.5 Million
Q1 2021 May 17, 2021	BUY	$87.57 - $119.4 $4.27 Million - $5.83 Million	48,791 New	48,791 $4.75 Million
Q3 2020 Nov 16, 2020	SELL	$96.16 - $135.15 $3.21 Million - $4.51 Million	-33,393 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$85.09 - $130.36 $109,681 - $168,034	-1,289 Reduced 3.72%	33,393 $4.07 Million
Q1 2020 May 15, 2020	BUY	$75.11 - $113.76 $2.6 Million - $3.95 Million	34,682 New	34,682 $3 Million

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Cinctive Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Cinctive Capital Management LP with notifications on news.